116 related articles for article (PubMed ID: 22104573)
1. Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome.
Schoenfeld JD; Mauch PM; Das P; Silver B; Marcus KJ; Stevenson MA; Ng AK
Ann Oncol; 2012 Jul; 23(7):1813-8. PubMed ID: 22104573
[TBL] [Abstract][Full Text] [Related]
2. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients.
Milano MT; Li H; Constine LS; Travis LB
Cancer; 2011 Dec; 117(24):5538-47. PubMed ID: 21692074
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related peripheral small cell lung carcinoma in a Hodgkin lymphoma survivor.
Gudapati P; Abouamara M
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35264395
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.
Almagro-Casado E; Sánchez A; Cantos B; Salas C; Pérez-Callejo D; Provencio M
Clin Transl Oncol; 2016 Jan; 18(1):99-106. PubMed ID: 26530956
[TBL] [Abstract][Full Text] [Related]
5. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma.
Chowdhry AK; McHugh C; Fung C; Dhakal S; Constine LS; Milano MT
Cancer; 2015 May; 121(9):1436-45. PubMed ID: 25572913
[TBL] [Abstract][Full Text] [Related]
6. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
Goyal A; O'Leary D; Goyal K; Rubin N; Janakiram M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1821-1829. PubMed ID: 34013554
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and prognosis of incidentally detected lung cancers.
Quadrelli S; Lyons G; Colt H; Chimondeguy D; Buero A
Int J Surg Oncol; 2015; 2015():287604. PubMed ID: 25685550
[TBL] [Abstract][Full Text] [Related]
8. Survival in patients with metachronous second primary lung cancer.
Ha D; Choi H; Chevalier C; Zell K; Wang XF; Mazzone PJ
Ann Am Thorac Soc; 2015 Jan; 12(1):79-84. PubMed ID: 25494009
[TBL] [Abstract][Full Text] [Related]
9. Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis.
Kocher F; Lunger F; Seeber A; Amann A; Pircher A; Hilbe W; Fiegl M
Clin Lung Cancer; 2016 Jan; 17(1):62-7.e1. PubMed ID: 26420370
[TBL] [Abstract][Full Text] [Related]
10. The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
Laurie SA; Kris MG; Portlock CS; Rosenzweig KE; Miller VA; Krug LM; Rusch VW
Cancer; 2002 Jul; 95(1):119-26. PubMed ID: 12115325
[TBL] [Abstract][Full Text] [Related]
11. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.
Swerdlow AJ; Higgins CD; Smith P; Cunningham D; Hancock BW; Horwich A; Hoskin PJ; Lister TA; Radford JA; Rohatiner AZ; Linch DC
J Clin Oncol; 2011 Nov; 29(31):4096-104. PubMed ID: 21969511
[TBL] [Abstract][Full Text] [Related]
12. Clinical course of thoracic cancers in Hodgkin's disease survivors.
Das P; Ng AK; Stevenson MA; Mauch PM
Ann Oncol; 2005 May; 16(5):793-7. PubMed ID: 15802277
[TBL] [Abstract][Full Text] [Related]
13. The characteristics and survival of second primary lung cancer after Hodgkin's lymphoma: A comparison with first primary lung cancer using the SEER database.
Lin L; Wang D; Chen H
PLoS One; 2023; 18(5):e0285766. PubMed ID: 37195975
[TBL] [Abstract][Full Text] [Related]
14. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.
Minn AY; Riedel E; Halpern J; Johnston LJ; Horning SJ; Hoppe RT; Goodman KA
Br J Haematol; 2012 Nov; 159(3):329-39. PubMed ID: 22966754
[TBL] [Abstract][Full Text] [Related]
16. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.
Haberer S; Belin L; Le Scodan R; Kirova YM; Savignoni A; Stevens D; Moisson P; Decaudin D; Pierga JY; Reyal F; Campana F; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e145-52. PubMed ID: 21605948
[TBL] [Abstract][Full Text] [Related]
17. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
18. Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma.
Kumar V; Garg M; Chandra AB; Mayorga VS; Ahmed S; Ailawadhi S
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):576-589.e1. PubMed ID: 29934060
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of second primary lung malignancy in patients with known breast cancer.
Kerendi F; Gal A; Corvera JS; Halkos ME; Miller JI
South Med J; 2009 Mar; 102(3):269-74. PubMed ID: 19204611
[TBL] [Abstract][Full Text] [Related]
20. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
Baras N; Dahm S; Haberland J; Janz M; Emrich K; Kraywinkel K; Salama A
Br J Haematol; 2017 Apr; 177(2):226-242. PubMed ID: 28106907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
